465 related articles for article (PubMed ID: 22237715)
1. Negative/low HER2 expression alone or combined with E-cadherin positivity is predictive of better prognosis in patients with breast carcinoma.
Karray-Chouayekh S; Trifa F; Khabir A; Sellami-Boudawara T; Frikha M; Gargouri A; Mokdad-Gargouri R
Histol Histopathol; 2012 Mar; 27(3):377-85. PubMed ID: 22237715
[TBL] [Abstract][Full Text] [Related]
2. Loss of expression and aberrant methylation of the CDH1 (E-cadherin) gene in breast cancer patients from Kashmir.
Asiaf A; Ahmad ST; Aziz SA; Malik AA; Rasool Z; Masood A; Zargar MA
Asian Pac J Cancer Prev; 2014; 15(15):6397-403. PubMed ID: 25124632
[TBL] [Abstract][Full Text] [Related]
3. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
[TBL] [Abstract][Full Text] [Related]
4. CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer.
Caldeira JR; Prando EC; Quevedo FC; Neto FA; Rainho CA; Rogatto SR
BMC Cancer; 2006 Mar; 6():48. PubMed ID: 16512896
[TBL] [Abstract][Full Text] [Related]
5. Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics.
Liu X; Zheng Y; Qiao C; Qv F; Wang J; Ding B; Sun Y; Wang Y
Diagn Pathol; 2015 May; 10():50. PubMed ID: 25956130
[TBL] [Abstract][Full Text] [Related]
6. Invasive micropapillary carcinoma of the breast has a better long-term survival than invasive ductal carcinoma of the breast in spite of its aggressive clinical presentations: a comparison based on large population database and case-control analysis.
Chen H; Wu K; Wang M; Wang F; Zhang M; Zhang P
Cancer Med; 2017 Dec; 6(12):2775-2786. PubMed ID: 29072365
[TBL] [Abstract][Full Text] [Related]
7. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
Singh K; Wang Y; Marketkar S; Kalife ET; Steinhoff MM
Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review.
Huang R; Ding P; Yang F
Drug Des Devel Ther; 2015; 9():5277-85. PubMed ID: 26425077
[TBL] [Abstract][Full Text] [Related]
9. HER2 as a prognostic factor in breast cancer.
Ménard S; Fortis S; Castiglioni F; Agresti R; Balsari A
Oncology; 2001; 61 Suppl 2():67-72. PubMed ID: 11694790
[TBL] [Abstract][Full Text] [Related]
10. High expression of heat shock protein 10 correlates negatively with estrogen/progesterone receptor status and predicts poor prognosis in invasive ductal breast carcinoma.
Chu S; Wen Q; Qing Z; Luo J; Wang W; Chen L; Feng J; Xu L; Zang H; Fan S
Hum Pathol; 2017 Mar; 61():173-180. PubMed ID: 27993580
[TBL] [Abstract][Full Text] [Related]
11. Aberrant methylation of RASSF1A is associated with poor survival in Tunisian breast cancer patients.
Karray-Chouayekh S; Trifa F; Khabir A; Boujelbane N; Sellami-Boudawara T; Daoud J; Frikha M; Jlidi R; Gargouri A; Mokdad-Gargouri R
J Cancer Res Clin Oncol; 2010 Feb; 136(2):203-10. PubMed ID: 19657672
[TBL] [Abstract][Full Text] [Related]
12. CpG methylation of APC promoter 1A in sporadic and familial breast cancer patients.
Debouki-Joudi S; Trifa F; Khabir A; Sellami-Boudawara T; Frikha M; Daoud J; Mokdad-Gargouri R
Cancer Biomark; 2017; 18(2):133-141. PubMed ID: 27983523
[TBL] [Abstract][Full Text] [Related]
13. Brief fixation enables same-day breast cancer diagnosis with reliable assessment of hormone receptors, E-cadherin and HER2/Neu.
Halilovic A; Bulte J; Jacobs Y; Braam H; van Cleef P; Schlooz-Vries M; Werner A; Boelens O; Nagtegaal I; de Wilt H; Bult P
J Clin Pathol; 2017 Sep; 70(9):781-786. PubMed ID: 28325747
[TBL] [Abstract][Full Text] [Related]
14. P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation.
Paredes J; Albergaria A; Oliveira JT; Jerónimo C; Milanezi F; Schmitt FC
Clin Cancer Res; 2005 Aug; 11(16):5869-77. PubMed ID: 16115928
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive factors of invasive ductal breast carcinomas.
Lialiaris TS; Georgiou G; Sivridis E; Kareli D; Tripsiannis G; Papageorgiou A; Chrisafi S; Kritsi Z; Giatromanolaki A
J BUON; 2010; 15(1):79-88. PubMed ID: 20414932
[TBL] [Abstract][Full Text] [Related]
16. Basal-like immunophenotype markers and prognosis in early breast cancer.
Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B
Tumori; 2010; 96(6):966-70. PubMed ID: 21388060
[TBL] [Abstract][Full Text] [Related]
17. Progesterone receptor status in determining the prognosis of estrogen receptor positive/ HER2 negative breast carcinoma patients.
Bal O; Yalcintas Arslan U; Durnali A; Uyetrk U; Demirci A; Tastekin D; Ekinci A; Esbah O; Turker I; Uysal Sonmez O; Oksuzoglu B
J BUON; 2015; 20(1):28-34. PubMed ID: 25778292
[TBL] [Abstract][Full Text] [Related]
18. [Cadherins E and P expression in the molecular types of breast cancer].
Fernández Á; Reigosa A; Caleiras E; Saldivia F; Hardisson D; Sanz F
Invest Clin; 2015 Jun; 56(2):155-68. PubMed ID: 26299056
[TBL] [Abstract][Full Text] [Related]
19. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
von Minckwitz G; Untch M; Blohmer JU; Costa SD; Eidtmann H; Fasching PA; Gerber B; Eiermann W; Hilfrich J; Huober J; Jackisch C; Kaufmann M; Konecny GE; Denkert C; Nekljudova V; Mehta K; Loibl S
J Clin Oncol; 2012 May; 30(15):1796-804. PubMed ID: 22508812
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]